10x Genomics Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating activities: | |||
| Net loss | $(255,099) | $(166,000) | $(58,223) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation expense | 166,950 | 136,848 | 95,962 |
| Depreciation and amortization | 35,512 | 25,368 | 21,118 |
| Asset impairment charges | 9,845 | — | — |
| Amortization of right-of-use assets | 8,107 | 7,638 | 7,136 |
| Realized loss on marketable securities | 1,718 | — | — |
| Other | 427 | 1,957 | 79 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (10,613) | (18,948) | (34,041) |
| Inventory | 7,871 | (21,192) | (30,132) |
| Prepaid expenses and other current assets | (2,429) | (4,495) | (1,053) |
| Other noncurrent assets | (678) | 925 | 1,045 |
| Accounts payable | (6,017) | 5,858 | 11,084 |
| Accrued compensation and other related benefits | (2,637) | 1,114 | 16,337 |
| Deferred revenue | 10,932 | 3,350 | 1,535 |
| Accrued contingent liabilities | — | — | (44,173) |
| Accrued expenses and other current liabilities | 28,301 | 3,336 | (873) |
| Operating lease liability | (8,671) | (6,423) | (2,469) |
| Other noncurrent liabilities | 1,284 | (2,942) | (4,705) |
| Net cash used in operating activities | (15,197) | (33,606) | (21,373) |
| Investing activities: | |||
| Proceeds from sales of marketable securities | 100,191 | 49,117 | — |
| Proceeds from maturities of marketable securities | 82,825 | 18,528 | — |
| Purchases of property and equipment | (48,601) | (131,661) | (101,278) |
| Purchase of intangible assets | (923) | — | — |
| Acquisition of business, net of cash acquired | — | (4,000) | (5,451) |
| Purchase of marketable securities | — | (282,871) | — |
| Net cash provided by (used in) investing activities | 133,492 | (350,887) | (106,729) |
| Financing activities: | |||
| Payments on technology license financing arrangement | (5,814) | (5,409) | (5,028) |
| Issuance of common stock from exercise of stock options and employee stock purchase plan purchases | 19,483 | 21,226 | 40,325 |
| Net cash provided by financing activities | 13,669 | 15,817 | 35,297 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (33) | (44) | 234 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 131,931 | (368,720) | (92,571) |
| Cash, cash equivalents, and restricted cash at beginning of year | 227,353 | 596,073 | 688,644 |
| Cash, cash equivalents, and restricted cash at end of year | $359,284 | $227,353 | $596,073 |
| Supplemental disclosures of cash flow information: | |||
| Cash paid for interest | $436 | $841 | $1,222 |
| Cash paid for taxes | $4,927 | $3,925 | $8,660 |
| Noncash investing and financing activities | |||
| Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities | $3,324 | $26,750 | $16,972 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $6,518 | $16,562 | $21,284 |
| Contingent consideration payable related to business acquisition | $— | $— | $1,500 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.